A prospective, single-center investigator-initiated study of Mavrilimumab for the treatment of patients COVID-19 infection

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 07 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Apr 2020 New trial record
31 Mar 2020 According to a Kiniksa Pharmaceuticals media release, Professor Lorenzo Dagna, MD, FACP (Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy) plans to initiate a prospective, single-center investigator-initiated study of Mavrilimumab, based on the initial results from the treatment protocol (n=6).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com